2L-rpRNAse-milatuzumab-g4P (Immunomedics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name2L-rpRNAse-milatuzumab-g4P (Immunomedics)

Drug Alias Name2L-Rap-milatuzumab-y4P (Immunomedics)2L-rpRNAse-hLL1-g4P (Immunomedics)immunotoxin (Immunomedics/Garden State Cancer Center)2L-Rap-IMMU-115-y4P (Immunomedics)2L-rpRNAse-IMMU-115-g4P (Immunomedics) +[6]

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate

Mechanisms of ActionHLA-DR antigens-associated invariant chain inhibitorsRibonucleases stimulants

TargetsRibonucleasesHLA-DR antigens-associated invariant chain

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A